Long-term study of semaglutide effects on heart, kidney, and metabolic health
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes or a body mass index of 27 or higher.
- You started taking semaglutide (or another diabetes medication) before January 1, 2023.
- You have seen an LMC endocrinologist in the past 18 months.
- You have had your hemoglobin A1c (a blood sugar test) measured within 6 months before your first dose.
- You have not been diagnosed with type 1 diabetes or a related autoimmune condition.
- You agree to let your medical records be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses MRI scans to look at how the diabetes medication semaglutide affects body composition in people with type 2 diabetes and obesity. It may help doctors understand how this treatment works in the body.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This study tests a new medicine called NNC0487-0111 to see how well it helps people with excess body weight and type 2 diabetes lose weight, compared to another medicine called semaglutide. It may be an option if you have type 2 diabetes and are looking to manage your weight.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
Hear when a new Diabetes (DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.